Trump highlights ibogaine in executive order on psychedelics

Trump highlights ibogaine in executive order on psychedelics

President Donald Trump has spotlighted ibogaine in a recent executive order, aiming to accelerate research and development of psychedelic drugs. This move is intended to streamline regulatory processes, potentially impacting the timeline for drug approvals.

Regulatory context

The executive order facilitates the transfer of an existing Investigational New Drug (IND) application, providing federal agencies and private sponsors with a foundational FDA file. This approach is designed to expedite the development process by building on existing documentation rather than starting anew. The order involves the Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), and the Department of Veterans Affairs (VA), and is framed within the "Right to Try" legislation.

What the order entails

The executive order directs federal agencies to accelerate the development of psychedelic drugs, including ibogaine. However, while the order can speed up processes like rescheduling or expanded access, full drug approval remains contingent on data and FDA evaluation. The order's impact will depend on subsequent actions by the Drug Enforcement Administration (DEA) and FDA, such as scheduling reviews and guidance updates.

Why it matters

The executive order could influence the psychedelic therapeutics market, potentially affecting small-cap drug developers. Historically, political endorsements have led to short-term market movements, but lasting impacts require concrete actions from regulatory agencies. The focus on ibogaine highlights its potential in treating conditions like opioid use disorder, PTSD, and traumatic brain injury, areas of significant public health concern.

This development underscores the ongoing interest in psychedelic drugs as potential therapeutic agents, with regulatory actions playing a crucial role in their future availability.